Prevent Further Organ Damage – Continued production of abnormal light chains leads to ongoing amyloid deposition, worsening organ failure. The sooner levels are controlled, the lower the risk of irreversible damage.
Improve Survival – High light chain burden is associated with worse outcomes. Studies show that patients who achieve a rapid and deep reduction in light chain levels have better survival rates.
Enhance Organ Function Recovery – Some organ damage may be reversible if amyloid deposition stops early enough, allowing the body to clear existing deposits over time.
Reduce Risk of Cardiac Involvement – The heart is one of the most critical organs affected in AL amyloidosis. If cardiac amyloidosis progresses, it can lead to heart failure and arrhythmias, which significantly shorten life expectancy.
Improve Response to Treatment – Many therapies (e.g., daratumumab, bortezomib, autologous stem cell transplant) aim to quickly reduce light chains. Delayed response may reduce the effectiveness of treatment and increase complications.